CFD and paroxysmal nocturnal hemoglobinuria: Danicopan (ALXN2040) is an oral small molecule complement factor D (FD) inhibitor that showed improved benefit-risk profile as add-on therapy to ravulizumab or eculizumab in patients with complement-mediated paroxysmal nocturnal hemoglobinuria (PNH) compared to placebo (132).